Multiply Labs
+134%
est. 2Y upside i
Robotic production capacity for the pharma manufacturing industry
Rank
#210
Sector
Biotechnology / Robotics
Est. Liquidity
~2Y
Data Quality
Data: LowMultiply Labs presents a high-risk, high-reward opportunity.
Last updated: July 19, 2026
Bull case: Successful IPO window or category leadership drives multiple expansion to 10x, with projected 2027 revenue of $12.5M yielding $125M exit. Dilution reduces net upside to 400%.
Base case: Multiple converges to public comp average of 6x, exit value $75M. 20% dilution reduces net upside to 234%.
Bear case: Multiple compresses to 3x, exit value $37.5M, below total funding of $41.3M, rendering common stock worthless after preference stack.
Preference Stack Risk
severeFunding Intensity
195%Total funding of $41.3M implies preferred stack exceeds current equity value, endangering common stock in downside.
Dilution Risk
highWith last round in 2023 and high capital intensity, a dilutive raise within 24 months is likely, assumed 20% dilution.
Secondary Liquidity
noneNo secondary market liquidity noted; illiquid until exit.
Hardware — 6 roles
- Electrical/Mechatronics Engineer II/III · San Francisco
- Hardware Reliability Engineer · San Francisco
- Mechanical Engineer - Consumables · San Francisco
- +3 more →
Robotics Software — 3 roles
- Robotics Field Engineer · Los Angeles
- Senior / Staff Robotics Software Engineer · San Francisco
- Senior Systems Integration Engineer · San Francisco
Software — 2 roles
- Senior / Staff Software Engineer · Boston
- Senior / Staff Software Engineer · San Francisco
Advanced Software R&D — 1 role
Biosciences — 1 role
- Scientist II · San Francisco
Engineering Leadership — 1 role
- VP of Software Engineering · San Francisco
Finance — 1 role
- Head of Finance · San Francisco
Open Application — 1 role
- Open Applications at Multiply Labs · San Francisco
Last updated: February 22, 2026
Questions to Ask at the Interview
Strategic questions based on Multiply Labs's data — designed to show you've done your homework.
- 1
“How does Multiply Labs' robotic platform differentiate from in-house automation efforts by large pharma incumbents like Thermo Fisher?”
- 2
“What is the recurring revenue component as a percentage of total revenue, and how do subscription agreements scale with customer growth?”
- 3
“Given the high preference stack and likely dilutive raise, how does the company plan to align employee equity incentives with long-term value creation?”
Community
Valuation Sentiment
Our model estimates +134% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.